Skip to main content
SpringerLink
Log in

Change of procalcitonin predicts clinical outcome of febrile episodes in patients with hematological malignancies

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Background

Procalcitonin (PCT) was widely investigated in febrile neutropenia as an indirect marker of infection. Many institutions also use PCT as a tool to monitor the course of a febrile episode because increases in PCT values during the febrile episode were associated with development of complications. However, to date, no study systematically evaluated the accuracy of decreasing PCT values in predicting favorable outcomes of a febrile episode. The aim of this study was to evaluate the changes in PCT values after resolution of fever with regard to their predictive value of stable defervescence.

Materials and methods

PCT was studied prospectively in 94 febrile episodes of 35 patients with hematological malignancies.

Results

Sixty-seven episodes were associated with an increased level of PCT at the beginning. In these episodes, stable resolution of fever was significantly correlated with a decrease in PCT values. The best cut-off level to predict freedom from recurrence of fever for at least 5 days was <70% of the maximum PCT value on the second afebrile day. Out of 44 patient episodes with a subsequent decrease to <70%, only two patients had recurrent fever within the next 5 days, revealing a negative predictive value of 95%, p<0.001.

Conclusion

Our study supports the value of PCT as a reliable tool to predict clinical outcome in febrile neutropenia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Barnes C, Ignjatovic V, Newall F, Carlin J, Ng F, Hamilton S, Ashley D, Waters K, Monagle P (2002) Change in serum procalcitonin (deltaPCT) predicts the clinical outcome of children admitted with febrile neutropenia. Br J Haematol 118:1197–1198

    Article  PubMed  Google Scholar 

  2. Bernard L, Ferriere F, Casassus P, Malas F, Leveque S, Guillevin L, Lortholary O (1998) Procalcitonin as an early marker of bacterial infection in severely neutropenic febrile adults. Clin Infect Dis 27:914–915

    Article  PubMed  CAS  Google Scholar 

  3. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, Muller B (2004) Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 363:600–607

    Article  PubMed  CAS  Google Scholar 

  4. Donowitz GR, Maki DG, Crnich CJ, Pappas PG, Rolston KV (2001) Infections in the neutropenic patient—new views of an old problem. Hematology (Am Soc Hematol Educ Program) 113–139

  5. Engel A, Steinbach G, Kern P, Kern WV (1999) Diagnostic value of procalcitonin serum levels in neutropenic patients with fever: comparison with interleukin-8. Scand J Infect Dis 31:185–189

    Article  PubMed  CAS  Google Scholar 

  6. Fleischhack G, Kambeck I, Cipic D, Hasan C, Bode U (2000) Procalcitonin in paediatric cancer patients: its diagnostic relevance is superior to that of C-reactive protein, interleukin 6, interleukin 8, soluble interleukin 2 receptor and soluble tumour necrosis factor receptor II. Br J Haematol 111:1093–1102

    Article  PubMed  CAS  Google Scholar 

  7. Giamarellos-Bourboulis EJ, Grecka P, Poulakou G, Anargyrou K, Katsilambros N, Giamarellou H (2001) Assessment of procalcitonin as a diagnostic marker of underlying infection in patients with febrile neutropenia. Clin Infect Dis 32:1718–1725

    Article  PubMed  CAS  Google Scholar 

  8. Giamarellou H, Giamarellos-Bourboulis EJ, Repoussis P, Galani L, Anagnostopoulos N, Grecka P, Lubos D, Aoun M, Athanassiou K, Bouza E, Devigili E, Krcmery V, Menichetti F, Panaretou E, Papageorgiou E, Plachouras D (2004) Potential use of procalcitonin as a diagnostic criterion in febrile neutropenia: experience from a multicentre study. Clin Microbiol Infect 10:628–633

    Article  PubMed  CAS  Google Scholar 

  9. Hambach L, Eder M, Dammann E, Schrauder A, Sykora KW, Dieterich C, Kirschner P, Novotny J, Ganser A, Hertenstein B (2002) Diagnostic value of procalcitonin serum levels in comparison with C-reactive protein in allogeneic stem cell transplantation. Haematologica 87:643–651

    PubMed  CAS  Google Scholar 

  10. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751

    Article  PubMed  Google Scholar 

  11. Jimeno A, Garcia-Velasco A, del Val O, Gonzalez-Billalabeitia E, Hernando S, Hernandez R, Sanchez-Munoz A, Lopez-Martin A, Duran I, Robles L, Cortes-Funes H, Paz-Ares L (2004) Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. Cancer 100:2462–2469

    Article  PubMed  CAS  Google Scholar 

  12. Kallio R, Surcel HM, Bloigu A, Syrjala H (2000) C-reactive protein, procalcitonin and interleukin-8 in the primary diagnosis of infections in cancer patients. Eur J Cancer 36:889–894

    Article  PubMed  CAS  Google Scholar 

  13. Link H, Bohme A, Cornely OA, Hoffken K, Kellner O, Kern WV, Mahlberg R, Maschmeyer G, Nowrousian MR, Ostermann H, Ruhnke M, Sezer O, Schiel X, Wilhelm M, Auner HW (2003) Antimicrobial therapy of unexplained fever in neutropenic patients-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 82:S105–S117

    Article  PubMed  CAS  Google Scholar 

  14. Ortega M, Rovira M, Filella X, Almela M, Puig de la Bellacasa J, Carreras E, Mensa J (2004) Prospective evaluation of procalcitonin in adults with febrile neutropenia after haematopoietic stem cell transplantation. Br J Haematol 126:372–376

    Article  PubMed  CAS  Google Scholar 

  15. Persson L, Engervall P, Magnuson A, Vikerfors T, Soderquist B, Hansson LO, Tidefelt U (2004) Use of inflammatory markers for early detection of bacteraemia in patients with febrile neutropenia. Scand J Infect Dis 36:365–371

    Article  PubMed  CAS  Google Scholar 

  16. Persson L, Soderquist B, Engervall P, Vikerfors T, Hansson LO, Tidefelt U (2005) Assessment of systemic inflammation markers to differentiate a stable from a deteriorating clinical course in patients with febrile neutropenia. Eur J Haematol 74:297–303

    Article  PubMed  CAS  Google Scholar 

  17. Ruokonen E, Nousiainen T, Pulkki K, Takala J (1999) Procalcitonin concentrations in patients with neutropenic fever. Eur J Clin Microbiol Infect Dis 18:283–285

    Article  PubMed  CAS  Google Scholar 

  18. Svaldi M, Hirber J, Lanthaler AI, Mayr O, Faes S, Peer E, Mitterer M (2001) Procalcitonin-reduced sensitivity and specificity in heavily leucopenic and immunosuppressed patients. Br J Haematol 115:53–57

    Article  PubMed  CAS  Google Scholar 

  19. Uys A, Rapoport BL, Anderson R (2004) Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer 12:555–560

    Article  PubMed  Google Scholar 

  20. von Lilienfeld-Toal M, Dietrich MP, Glasmacher A, Lehmann L, Breig P, Hahn C, Schmidt-Wolf IG, Marklein G, Schroeder S, Stuber F (2004) Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein. Eur J Clin Microbiol Infect Dis 23:539–544

    Article  PubMed  CAS  Google Scholar 

  21. Zweig MH, Campbell G (1993) Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39:561–577

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by the Leukaemie-Initiative Bonn. M. von Lilienfeld-Toal is supported by a grant from BonFor, University of Bonn. We thank Makbule Kobilay for excellent technical assistance and Samuel Ackroyd for critical reading of the manuscript.

Author information

Authors and Affiliations

  1. Medizinische Klinik und Poliklinik I, Universitätsklinikum Bonn, Sigmund Freud Street 25, 53105, Bonn, Germany

    M. von Lilienfeld-Toal, K. Orlopp, C. Hahn-Ast & A. Glasmacher

  2. Klinik für Anästhesiologie und Spezielle Intensivmedizin, Universitätsklinikum Bonn, Sigmund Freud Street 25, 53105, Bonn, Germany

    A. Schneider & F. Stüber

Authors
  1. M. von Lilienfeld-Toal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Orlopp
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Hahn-Ast
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Glasmacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F. Stüber
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. von Lilienfeld-Toal.

Rights and permissions

Reprints and permissions

About this article

Cite this article

von Lilienfeld-Toal, M., Schneider, A., Orlopp, K. et al. Change of procalcitonin predicts clinical outcome of febrile episodes in patients with hematological malignancies. Support Care Cancer 14, 1241–1245 (2006). https://doi.org/10.1007/s00520-006-0081-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-006-0081-2

Keywords

Search

Navigation